دورية أكاديمية
أعرض في EDS

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.

التفاصيل البيبلوغرافية
العنوان: Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.
المؤلفون: Lin CP; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Levy PL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Tumor Immunology and Immunotherapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Alflen A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany; Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany., Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Alkan F; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Malka Y; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Markovits E; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel., George A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Traets JJH; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Vliet A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Poźniak J; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Pulido-Vicuña CA; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Hal-van Veen SE; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van der Helm PW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Díaz-Gómez J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Warda H; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Behrens LM; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Mardesic P; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Dehni B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Visser NL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Marine JC; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Markel G; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel., Faller WJ; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands., Agami R; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Besser MJ; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Pathology, VU University Amsterdam, 1081 HV Amsterdam, the Netherlands. Electronic address: d.peeper@nki.nl.
المصدر: Cancer cell [Cancer Cell] 2024 Apr 08; Vol. 42 (4), pp. 623-645.e10. Date of Electronic Publication: 2024 Mar 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101130617 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3686 (Electronic) Linking ISSN: 15356108 NLM ISO Abbreviation: Cancer Cell Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, Mass. : Cell Press, c2002-
مواضيع طبية MeSH: CRISPR-Cas Systems* , Neoplasms*/genetics, Humans ; CD8-Positive T-Lymphocytes
مستخلص: Genes limiting T cell antitumor activity may serve as therapeutic targets. It has not been systematically studied whether there are regulators that uniquely or broadly contribute to T cell fitness. We perform genome-scale CRISPR-Cas9 knockout screens in primary CD8 T cells to uncover genes negatively impacting fitness upon three modes of stimulation: (1) intense, triggering activation-induced cell death (AICD); (2) acute, triggering expansion; (3) chronic, causing dysfunction. Besides established regulators, we uncover genes controlling T cell fitness either specifically or commonly upon differential stimulation. Dap5 ablation, ranking highly in all three screens, increases translation while enhancing tumor killing. Loss of Icam1-mediated homotypic T cell clustering amplifies cell expansion and effector functions after both acute and intense stimulation. Lastly, Ctbp1 inactivation induces functional T cell persistence exclusively upon chronic stimulation. Our results functionally annotate fitness regulators based on their unique or shared contribution to traits limiting T cell antitumor activity.
Competing Interests: Declaration of interests C.L., P.L., A.A., G.A., M.A.L., D.W.V., and D.S.P. are named as inventors on a patent filed by the Netherlands Cancer Institute and Oncode on the findings described in this manuscript. D.S.P. and M.A.L. are co-founders, shareholders, and advisors of Immagene.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
J Leukoc Biol. 2020 Jun;107(6):883-892. (PMID: 32386455)
Mol Cell Biol. 1999 Jan;19(1):612-22. (PMID: 9858585)
EMBO J. 2023 Mar 1;42(5):e111614. (PMID: 36715448)
Science. 2018 Feb 16;359(6377):770-775. (PMID: 29301958)
Mol Ther. 2016 Jun;24(6):1135-1149. (PMID: 27019998)
Nucleic Acids Res. 2015 Apr 20;43(7):3764-75. (PMID: 25779044)
Nature. 2019 Jul;571(7764):270-274. (PMID: 31207604)
N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Nature. 2006 Feb 9;439(7077):682-7. (PMID: 16382236)
Nat Commun. 2022 Feb 10;13(1):805. (PMID: 35145086)
J Exp Med. 2005 Oct 3;202(7):907-12. (PMID: 16203864)
Immunity. 2012 Dec 14;37(6):1130-44. (PMID: 23159438)
Nat Immunol. 2013 Apr;14(4):356-63. (PMID: 23475183)
Nat Immunol. 2011 Jun;12(6):492-9. (PMID: 21739672)
Front Immunol. 2019 May 22;10:1078. (PMID: 31231358)
Mol Cell Biol. 1997 Mar;17(3):1615-25. (PMID: 9032289)
Nat Immunol. 2009 Jan;10(1):29-37. (PMID: 19043418)
Science. 2002 Oct 25;298(5594):850-4. (PMID: 12242449)
Front Oncol. 2023 Mar 03;13:1116328. (PMID: 36937426)
Nucleic Acids Res. 2016 May 5;44(8):3567-85. (PMID: 26673693)
Cancer Cell. 2018 Apr 9;33(4):547-562. (PMID: 29634943)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
EMBO J. 2006 Sep 6;25(17):4008-19. (PMID: 16932749)
EMBO J. 1985 May;4(5):1251-5. (PMID: 4006916)
Nature. 1995 Feb 2;373(6513):444-8. (PMID: 7530337)
Hum Gene Ther Methods. 2014 Oct;25(5):277-87. (PMID: 25143008)
Cell. 2018 Nov 1;175(4):998-1013.e20. (PMID: 30388456)
Int Immunol. 2018 Nov 14;30(12):559-567. (PMID: 30085193)
Front Immunol. 2018 Dec 18;9:2981. (PMID: 30619337)
J Immunother Cancer. 2021 May;9(5):. (PMID: 33990415)
EMBO J. 1991 May;10(5):1245-54. (PMID: 2022189)
Int Immunol. 2005 Feb;17(2):133-44. (PMID: 15611321)
Nature. 2009 Oct 1;461(7264):659-63. (PMID: 19794494)
J Virol. 2005 Sep;79(18):12112-6. (PMID: 16140789)
Nat Med. 2000 May;6(5):493-5. (PMID: 10802692)
Nature. 2015 Jan 29;517(7536):583-8. (PMID: 25494202)
N Engl J Med. 2014 Oct 16;371(16):1507-17. (PMID: 25317870)
Science. 2022 Nov 11;378(6620):eabn5647. (PMID: 36356142)
Cell. 1994 Jan 14;76(1):17-27. (PMID: 8287475)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Nucleic Acids Res. 2008 Jan;36(1):168-78. (PMID: 18003655)
Cell. 2002 Dec 13;111(6):837-51. (PMID: 12526810)
Genomics. 1992 Jul;13(3):911-2. (PMID: 1386342)
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6683-8. (PMID: 10359772)
Nat Biotechnol. 2016 Feb;34(2):184-191. (PMID: 26780180)
J Cell Mol Med. 2020 Oct;24(19):11445-11456. (PMID: 32910558)
Nature. 1999 Oct 14;401(6754):708-12. (PMID: 10537110)
Cell. 2021 Mar 4;184(5):1262-1280.e22. (PMID: 33636129)
Nat Protoc. 2010 May;5(5):929-34. (PMID: 20431538)
Immunity. 2020 Feb 18;52(2):313-327.e7. (PMID: 32049052)
BMC Bioinformatics. 2020 May 15;21(1):191. (PMID: 32414321)
Methods Mol Biol. 2016;1355:251-60. (PMID: 26584931)
J Immunol. 2004 Dec 15;173(12):7125-30. (PMID: 15585832)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Nature. 2019 Jul;571(7764):265-269. (PMID: 31207605)
J Exp Med. 1992 Jan 1;175(1):185-90. (PMID: 1730916)
Cell. 2018 Dec 13;175(7):1958-1971.e15. (PMID: 30449619)
Gene. 2004 Dec 22;343(2):239-44. (PMID: 15588578)
J Exp Med. 2022 Feb 7;219(2):. (PMID: 34935874)
J Immunol. 2006 Dec 1;177(11):7515-9. (PMID: 17114419)
Immunity. 2007 Aug;27(2):281-95. (PMID: 17723218)
Cancer Discov. 2021 May;11(5):1192-1211. (PMID: 33328215)
Immunology. 2006 Jul;118(3):361-71. (PMID: 16827897)
Front Immunol. 2021 Jul 20;12:715234. (PMID: 34354714)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Nat Immunol. 2005 Dec;6(12):1236-44. (PMID: 16273099)
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1416-21. (PMID: 23297203)
J Immunol. 2013 Oct 1;191(7):3681-93. (PMID: 23997225)
Nat Commun. 2019 Dec 20;10(1):5817. (PMID: 31862961)
Nature. 2019 Dec;576(7787):471-476. (PMID: 31827283)
Cell. 2019 Aug 22;178(5):1189-1204.e23. (PMID: 31442407)
Nature. 2017 Aug 31;548(7669):537-542. (PMID: 28783722)
Nature. 2022 Mar;603(7902):728-735. (PMID: 35296855)
J Clin Invest. 2023 Jan 17;133(2):. (PMID: 36378537)
J Exp Med. 2015 Nov 16;212(12):2041-56. (PMID: 26503446)
Sci Transl Med. 2023 Apr 5;15(690):eabk1900. (PMID: 37018415)
Nat Genet. 2000 May;25(1):25-9. (PMID: 10802651)
J Exp Med. 2006 Oct 2;203(10):2281-92. (PMID: 16954372)
Cell. 2021 Jun 24;184(13):3573-3587.e29. (PMID: 34062119)
Cell. 2017 Apr 6;169(2):326-337.e12. (PMID: 28388414)
Nature. 2022 Sep;609(7925):174-182. (PMID: 36002574)
Genes Dev. 1997 Feb 1;11(3):321-33. (PMID: 9030685)
Immunity. 2020 Jul 14;53(1):143-157.e8. (PMID: 32640256)
J Exp Med. 2015 Nov 16;212(12):2027-39. (PMID: 26503445)
Nature. 2019 Apr;568(7753):511-516. (PMID: 30971826)
J Immunol. 2002 Jun 1;168(11):5530-7. (PMID: 12023348)
Immunity. 2015 Feb 17;42(2):265-278. (PMID: 25680272)
Front Cell Dev Biol. 2019 Oct 01;7:212. (PMID: 31632965)
J Clin Invest. 2011 Jun;121(6):2350-60. (PMID: 21555851)
Nat Immunol. 2000 Jul;1(1):23-9. (PMID: 10881170)
Nat Rev Immunol. 2012 Nov;12(11):749-61. (PMID: 23080391)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
Nat Commun. 2023 Feb 2;14(1):86. (PMID: 36732507)
Cell Rep. 2017 Aug 1;20(5):1017-1028. (PMID: 28768188)
Melanoma Res. 2023 Feb 1;33(1):12-26. (PMID: 36545919)
Eur J Immunol. 2005 Mar;35(3):738-45. (PMID: 15724249)
Sci Immunol. 2021 Dec 03;6(66):eabe8219. (PMID: 34860579)
J Clin Invest. 2007 Nov;117(11):3383-92. (PMID: 17932562)
Mol Cancer Ther. 2017 Jun;16(6):981-990. (PMID: 28576945)
J Exp Med. 1995 Jan 1;181(1):71-7. (PMID: 7528780)
Gene Ther. 2000 Jun;7(12):1063-6. (PMID: 10871756)
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5400-5. (PMID: 11943866)
Biomark Res. 2020 Sep 29;8:49. (PMID: 33005420)
Oncol Lett. 2021 Nov;22(5):810. (PMID: 34630717)
Genome Biol. 2014;15(12):554. (PMID: 25476604)
Immunity. 2016 Aug 16;45(2):415-27. (PMID: 27533016)
J Immunother Cancer. 2020 Aug;8(2):. (PMID: 32753545)
Immunity. 2017 Dec 19;47(6):1129-1141.e5. (PMID: 29246443)
Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. (PMID: 36370105)
J Exp Med. 2018 Apr 2;215(4):1153-1168. (PMID: 29449309)
Cancers (Basel). 2022 Aug 29;14(17):. (PMID: 36077730)
J Biol Chem. 2000 Aug 4;275(31):23409-12. (PMID: 10801898)
Nat Immunol. 2003 Dec;4(12):1191-8. (PMID: 14625547)
Cancer Immunol Res. 2018 Jun;6(6):733-744. (PMID: 29653982)
Nature. 2006 Sep 21;443(7109):350-4. (PMID: 16921384)
Mol Cell Biol. 1997 Dec;17(12):6940-7. (PMID: 9372926)
J Clin Oncol. 2017 Dec 1;35(34):3807-3814. (PMID: 28841387)
PLoS One. 2011;6(7):e21800. (PMID: 21789182)
Nucleic Acids Res. 2019 Jul 02;47(W1):W171-W174. (PMID: 31106371)
Nature. 2017 Jul 27;547(7664):413-418. (PMID: 28723893)
Cancer Discov. 2017 Feb;7(2):188-201. (PMID: 27903500)
N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456)
Nucleic Acids Res. 2021 Jan 8;49(D1):D1420-D1430. (PMID: 33179754)
Nat Med. 2006 Oct;12(10):1198-202. (PMID: 16917489)
Cancer Cell. 2022 Jul 11;40(7):768-786.e7. (PMID: 35750052)
Cell. 2003 Jan 10;112(1):99-111. (PMID: 12526797)
Genes Dev. 1998 Feb 15;12(4):502-13. (PMID: 9472019)
Nat Genet. 2003 Jul;34(3):267-73. (PMID: 12808457)
Mol Cell Biol. 2000 Jan;20(2):496-506. (PMID: 10611228)
N Engl J Med. 2019 Oct 17;381(16):1535-1546. (PMID: 31562797)
Nature. 2017 May 25;545(7655):452-456. (PMID: 28514453)
Nat Rev Clin Oncol. 2019 Jun;16(6):372-385. (PMID: 30837712)
Science. 2022 Feb 4;375(6580):eabj4008. (PMID: 35113687)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Cell. 1989 Jun 30;57(7):1083-93. (PMID: 2525423)
Genome Biol. 2014 Feb 03;15(2):R29. (PMID: 24485249)
Immunol Cell Biol. 2002 Apr;80(2):131-7. (PMID: 11940113)
Cancer Cell Int. 2013 Aug 06;13(1):78. (PMID: 23915418)
Cell. 2021 Mar 4;184(5):1245-1261.e21. (PMID: 33636132)
Cell Metab. 2022 Apr 5;34(4):595-614.e14. (PMID: 35276062)
Cell. 2019 Feb 7;176(4):882-896.e18. (PMID: 30639098)
Nature. 2019 Mar;567(7749):525-529. (PMID: 30814730)
Cell Cycle. 2009 Jan 15;8(2):204-9. (PMID: 19158497)
Immunity. 2016 Aug 16;45(2):389-401. (PMID: 27521269)
EClinicalMedicine. 2021 Sep 16;41:101134. (PMID: 34585125)
Cancers (Basel). 2023 Feb 04;15(4):. (PMID: 36831349)
Nat Med. 2018 May;24(5):563-571. (PMID: 29713085)
Crit Rev Immunol. 2014;34(4):301-14. (PMID: 24941158)
Nature. 2021 Dec;600(7888):308-313. (PMID: 34795452)
Clin Cancer Res. 2010 May 1;16(9):2646-55. (PMID: 20406835)
Immunity. 2021 Mar 9;54(3):571-585.e6. (PMID: 33497609)
Sci Immunol. 2018 May 18;3(23):. (PMID: 29776993)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Curr Opin Cell Biol. 1997 Oct;9(5):643-50. (PMID: 9330867)
Nat Rev Immunol. 2015 Aug;15(8):486-99. (PMID: 26205583)
Nat Immunol. 2018 Oct;19(10):1112-1125. (PMID: 30224822)
Behav Res Methods. 2007 May;39(2):175-91. (PMID: 17695343)
J Biol Chem. 2001 May 4;276(18):14642-8. (PMID: 11279101)
J Exp Med. 2003 Aug 18;198(4):569-80. (PMID: 12925674)
Nature. 2019 Jul;571(7764):211-218. (PMID: 31207603)
Nat Commun. 2017 May 31;8:15440. (PMID: 28561041)
Nature. 2019 Dec;576(7786):293-300. (PMID: 31802004)
PLoS One. 2014 May 14;9(5):e96650. (PMID: 24827921)
Front Immunol. 2019 Jul 31;10:1818. (PMID: 31417576)
Front Immunol. 2018 May 03;9:952. (PMID: 29774029)
Immune Netw. 2020 May 20;20(3):e20. (PMID: 32655968)
Clin Immunol. 2003 Jul;108(1):8-20. (PMID: 12865066)
Nat Immunol. 2022 Nov;23(11):1600-1613. (PMID: 36271148)
Cell Mol Immunol. 2021 Sep;18(9):2140-2152. (PMID: 32398809)
Nature. 2020 Oct;586(7827):120-126. (PMID: 32968282)
EMBO J. 1997 Feb 17;16(4):817-25. (PMID: 9049310)
Cancer Cell. 2020 Jun 8;37(6):818-833.e9. (PMID: 32516591)
N Engl J Med. 2013 Jul 11;369(2):122-33. (PMID: 23724867)
Cell. 2014 Oct 9;159(2):440-55. (PMID: 25263330)
Mol Cell Proteomics. 2014 Sep;13(9):2513-26. (PMID: 24942700)
Nat Commun. 2021 May 20;12(1):2965. (PMID: 34017005)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
Mol Carcinog. 2020 Jul;59(7):736-744. (PMID: 32250515)
Front Immunol. 2018 Sep 12;9:2084. (PMID: 30258446)
Front Immunol. 2018 Jun 11;9:1303. (PMID: 29942308)
Immunity. 2014 Aug 21;41(2):325-38. (PMID: 25148027)
Genetics. 2023 May 4;224(1):. (PMID: 36866529)
Dev Biol. 2007 Jun 1;306(1):34-49. (PMID: 17442301)
Nat Immunol. 2001 May;2(5):423-9. (PMID: 11323696)
Nature. 2023 Dec;624(7990):154-163. (PMID: 37968405)
Cold Spring Harb Symp Quant Biol. 2013;78:51-60. (PMID: 24163394)
Science. 2006 Oct 6;314(5796):126-9. (PMID: 16946036)
Pigment Cell Melanoma Res. 2014 May;27(3):495-501. (PMID: 24460976)
Cell. 2017 Jul 27;170(3):564-576.e16. (PMID: 28753430)
Cancer Cell. 2017 Mar 13;31(3):311-325. (PMID: 28292435)
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319)
Science. 2016 Dec 2;354(6316):1165-1169. (PMID: 27789799)
Science. 2012 Nov 30;338(6111):1220-5. (PMID: 23197535)
Nat Commun. 2017 Nov 10;8(1):1404. (PMID: 29123081)
EBioMedicine. 2022 Sep;83:104216. (PMID: 35986950)
Cancer Immunol Res. 2015 Apr;3(4):368-79. (PMID: 25576337)
Oncogene. 2007 Oct 25;26(49):6979-88. (PMID: 17486063)
J Cell Physiol. 2000 Mar;182(3):311-22. (PMID: 10653597)
Semin Immunol. 2016 Feb;28(1):28-34. (PMID: 26976826)
Immunol Cell Biol. 1999 Aug;77(4):312-7. (PMID: 10457197)
Bioinformatics. 2017 Jan 1;33(1):139-141. (PMID: 27634950)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Nat Methods. 2016 Sep;13(9):731-40. (PMID: 27348712)
Immunity. 2023 Jun 13;56(6):1320-1340.e10. (PMID: 37315535)
J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33462140)
Nat Rev Immunol. 2002 Apr;2(4):251-62. (PMID: 12001996)
J Immunol. 2008 May 1;180(9):5935-45. (PMID: 18424713)
Nat Immunol. 2011 May 29;12(7):663-71. (PMID: 21623380)
Cancer Res. 2018 Jan 1;78(1):115-128. (PMID: 29066514)
Cell Rep Med. 2022 Jun 21;3(6):100655. (PMID: 35688159)
Annu Rev Immunol. 2007;25:619-47. (PMID: 17201681)
Trends Cell Biol. 2014 Jul;24(7):400-6. (PMID: 24698685)
Sci Immunol. 2023 Aug 25;8(86):eade3369. (PMID: 37595022)
Trends Immunol. 2019 May;40(5):431-446. (PMID: 30956067)
Mol Cell. 2008 May 23;30(4):447-59. (PMID: 18450493)
Cell. 2016 Oct 6;167(2):397-404.e9. (PMID: 27667683)
Mol Cell. 2002 Feb;9(2):213-24. (PMID: 11864595)
N Engl J Med. 2016 Sep 1;375(9):819-29. (PMID: 27433843)
Oncol Rep. 2013 Aug;30(2):809-14. (PMID: 23756565)
Science. 1989 Apr 14;244(4901):217-21. (PMID: 2649981)
J Exp Med. 2001 Oct 1;194(7):953-66. (PMID: 11581317)
Curr Protoc Immunol. 2009 Nov;Chapter 18:18.16.1-18.16.20. (PMID: 19918947)
Cytometry. 1998 Jan 1;31(1):1-9. (PMID: 9450519)
Hum Cell. 2022 Mar;35(2):441-447. (PMID: 35032297)
Sci Immunol. 2020 Jul 3;5(49):. (PMID: 32620560)
Cell. 2019 Jul 25;178(3):585-599.e15. (PMID: 31303383)
J Immunol. 2005 Oct 1;175(7):4686-96. (PMID: 16177116)
Immunol Rev. 2013 Nov;256(1):148-59. (PMID: 24117819)
Nature. 2020 Jun;582(7812):416-420. (PMID: 32499641)
PLoS Pathog. 2015 Oct 20;11(10):e1005177. (PMID: 26485519)
فهرسة مساهمة: Keywords: CRISPR-Cas9 screen; Ctbp1; Dap5; Icam1; T cells; activation-induced cell death; cancer immunotherapy; dysfunction; effector function; exhaustion
تواريخ الأحداث: Date Created: 20240315 Date Completed: 20240411 Latest Revision: 20240411
رمز التحديث: 20240411
مُعرف محوري في PubMed: PMC11003465
DOI: 10.1016/j.ccell.2024.02.016
PMID: 38490212
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-3686
DOI:10.1016/j.ccell.2024.02.016